Prof Constantine Tam speaks to ecancer at the 2019 ASH meeting in Orlando about the latest results from the CAPTIVATE study which investigated the combination of ibrutinib plus venetoclax for the first-line treatment of chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL).
He outlines the design and results of the study, in which the oral agents were both well tolerated. The discontinuation rate was less than 5 percent, with 90 percent of patients completing the treatment sequence.
Prof Tam mentions that deep responses were achieved in these patients, as the MRD clearance rate was also found to be 75 percent. This novel therapy combination will allow patients to undergo treatment for a fixed duration of time and achieve good remission.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.